Aicuris Anti Infective Cures Ag Is A Clinical Stage Biopharmaceutical Company Based In Wuppertalgermanyfounded In 2006 As A Spin Off From Bayeraicuris Focuses On Developing And Commercializing Anti Infective Therapies Specifically For Immunocompromised Patientsthe Company Transitioned To A Stock Corporation In 2021 To Support Its Growth And Has Recently Shifted Its Strategic Focus To Exclusively Address The Needs Of This Vulnerable Population The Company S Pipeline Includes Several Key Candidatespritelivir Is A Late Stage Therapy Targeting Recurrent Herpes Simplex Virus Infections In Immunocompromised Patientsthe Adenovirus Program Is Developing An Oral Antiviral For Systemic Adenovirus Infectionsparticularly In Transplant Recipientsadditionallyprevymisa Letermovir Co Developed With Merck & Co Is A Successful Prophylaxis Therapy For Cytomegalovirus In Transplant Medicineaicuris Emphasizes Rapid Clinical Development And Aims To Improve Patient Accessibility Through Oral Formulations
